Home Cart Sign in  
Chemical Structure| 1835256-48-8 Chemical Structure| 1835256-48-8

Structure of Dersimelagon
CAS No.: 1835256-48-8

Chemical Structure| 1835256-48-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dersimelagon is an orally active selective melanocortin 1 receptor (MC1R) agonist, with EC50 values of 8.16, 3.91, 1.14, and 0.251 nM for human, crab-eating macaque, mouse, and rat MC1R, respectively. It is used for the study of skin pigmentation.

Synonyms: MT-7117

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dersimelagon

CAS No. :1835256-48-8
Formula : C36H45F4N3O5
M.W : 675.75
SMILES Code : O=C(C1CCN(C2=CC(C(F)(F)F)=CC=C2[C@H]3CN(C([C@]4(F)CN(C5CCCC5)C[C@H]4C6=CC=C(OC)C=C6)=O)C[C@@H]3COC)CC1)O
Synonyms :
MT-7117
MDL No. :N/A

Safety of Dersimelagon

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Dersimelagon

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04793295 Healthy Subjects PHASE1 COMPLETED 2022-02-04 Advanced Pharma CR, LLC, Miami... More >>, Florida, 33147, United States|Worldwide Clinical Trials, San Antonio, Texas, 78217, United States Less <<
NCT04656795 Renal Impairment|Normal Renal ... More >>Function Less << PHASE1 COMPLETED 2021-12-09 Clinical Research Services (CR... More >>S) Kiel GmbH, Kiel, Germany Less <<
NCT04116476 Mild and Moderate Hepatic Impa... More >>irment Less << PHASE1 COMPLETED 2021-02-16 University of Miami Clinical P... More >>harmacology Unit, Miami, Florida, 33136, United States Less <<
NCT05005975 EPP|XLP PHASE3 RECRUITING 2025-12-27 Marvel Clinical Research, LLC,... More >> Huntington Beach, California, 92647, United States|University of California at San Francisco - CSF Porphyria Center, San Francisco, California, 94143, United States|University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, 33136, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|MetroBoston Clinical Partners, LLC, Brighton, Massachusetts, 02135-3211, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Kansas City Research Institute, Kansas City, Missouri, 64131, United States|Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH), New York, New York, 10029, United States|Wake Forest University Baptist Health, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, 44106, United States|Remington-Davis Clinical Research, Columbus, Ohio, 43215, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Einstein Medical Center, Philadelphia, Philadelphia, Pennsylvania, 19141, United States|The University of Texas Medical Branch (UTMB), Galveston, Texas, 77555, United States|University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia|Wesley Medical Research, Brisbane, Queensland, 4066, Australia|Royal Melbourne Hospital (RMH), Parkville, Victoria, 3050, Australia|University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski, Sophia, 1000, Belgium|University of Alberta Hospital, Edmonton, Alberta, Edmonton AB T6G 2G3, Canada|Institute for Clinical and Experimental Medicine - IKEM, Praha, 140 21, Czechia|Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre, Bordeaux, 33000, France|Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier, Colombes, 92700, France|CHU Nantes, Nantes, 44000, France|Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine, Paris, 75018, France|Charite - Universitaetsmedizin Berlin, Berlin, 10117, Germany|Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia, Brescia BS, 25123, Italy|Azienda Sanitaria Ospedaliera Santa Croce E Carle - Cuneo, Cuneo CN, 12100, Italy|Ospedalle Galliera, Genova GE, 16128, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, 20122, Italy|U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena, Modena, 41125, Italy|IFO-San Gallicano IRCCS, Rome, 5300144, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Materno-Infantile - Burlo Garofolo - Clinica Pediatrica, Trieste TS, 34137, Italy|Kobe University Hospital, Kobe, Hyogo, 650-0017, Japan|Sophia Dermatology Clinic, Kanazawa, Ishikawa, 921-8035, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, 569-8686, Japan|Tokyo Saiseikai Central Hospital, Minato-ku, Tokyo, 108-0073, Japan|Toyama University Hospital, Sugitani, Toyama, 930-0194, Japan|Mazda Hospital of Mazda Motor Corporation, Hiroshima, 730-8670, Japan|Hamamatsu University Hospital, Shizuoka, 431-3125, Japan|Erasmus MC, Universitair Medisch Centrum Rotterdam, Rotterdam, 3015 GD, Netherlands|Haukeland University Hospital, Bergen, N5021, Norway|Instytut hematologii i Transfuzjologii, Warszawa, 02-776, Poland|Hospital Clínic de Barcelona, Barcelona, 8036, Spain|Hospital Universitario, Madrid, 28041, Spain|Hospital General Universitario De Valencia, Valencia, 46014, Spain|Karolinska University Hospital, Stockholm, 14186, Sweden|Salford Royal NHS Foundation Trust, Manchester, MN, M6 8HD, United Kingdom|St. John's Institute of Dermatology-Guy's & St Thomas' NHS Foundation Trust, London, SE1 7EH, United Kingdom|Evelina London Children's Hospital - Guy's & St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|Southampton General Hospital - University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.48mL

0.30mL

0.15mL

7.40mL

1.48mL

0.74mL

14.80mL

2.96mL

1.48mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories